Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Chemotherapy Induced Anemia Overview 8 Therapeutics Development 9 Pipeline Products for Chemotherapy Induced Anemia - Overview 9 Chemotherapy Induced Anemia - Therapeutics under Development by Companies 10 Chemotherapy Induced Anemia - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Chemotherapy Induced Anemia - Products under Development by Companies 15 Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 16 3SBio Inc. 16 BIOCAD 17 Chong Kun Dang Pharmaceutical Corp. 18 Dr. Reddy's Laboratories Limited 19 Galenica Ltd. 20 Panacea Biotec Limited 21 Pfizer Inc. 22 PharmaEssentia Corporation 23 PhytoHealth Corporation 24 Pieris Pharmaceuticals Inc 25 Sandoz International GmbH 26 SBI Pharmaceuticals Co., Ltd. 27 Therapure Biopharma Inc. 28 Tolero Pharmaceuticals, Inc. 29 Chemotherapy Induced Anemia - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 darbepoetin alfa - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 darbepoetin alfa - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 darbepoetin alfa - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 darbepoetin alfa - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 darbepoetin alfa - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 epoetin alfa - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 epoetin zeta - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ferric carboxymaltose - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 P-1116 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 PHN-013 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 PRS-080 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SSS-06 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 TBI-304H - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 TP-0184 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 TP-0413 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 TXA-302 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Chemotherapy Induced Anemia - Dormant Projects 63 Chemotherapy Induced Anemia - Discontinued Products 64 Chemotherapy Induced Anemia - Product Development Milestones 65 Featured News & Press Releases 65 Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H 65 Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia 65 Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 65 Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 66 Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 66 Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 67 Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 67 Aug 09, 2010: Dr Reddy’s Launches Darbepoetin Alfa For Treatment Of Anemia In India 68 Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world’s first complex biosimilar 68 Jan 07, 2008: Sandoz and Gambro form strategic alliance 69 Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71

List of Tables Number of Products under Development for Chemotherapy Induced Anemia, H2 2016 9 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H2 2016 16 Chemotherapy Induced Anemia - Pipeline by BIOCAD, H2 2016 17 Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 18 Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 19 Chemotherapy Induced Anemia - Pipeline by Galenica Ltd., H2 2016 20 Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H2 2016 21 Chemotherapy Induced Anemia - Pipeline by Pfizer Inc., H2 2016 22 Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corporation, H2 2016 23 Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corporation, H2 2016 24 Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 25 Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H2 2016 26 Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 27 Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H2 2016 28 Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Assessment by Combination Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Chemotherapy Induced Anemia - Dormant Projects, H2 2016 63 Chemotherapy Induced Anemia - Discontinued Products, H2 2016 64 List of Figures Number of Products under Development for Chemotherapy Induced Anemia, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Assessment by Monotherapy Products, H2 2016 30 Number of Products by Targets, H2 2016 32 Number of Products by Stage and Targets, H2 2016 32 Number of Products by Mechanism of Actions, H2 2016 34 Number of Products by Stage and Mechanism of Actions, H2 2016 34 Number of Products by Routes of Administration, H2 2016 36 Number of Products by Stage and Routes of Administration, H2 2016 36 Number of Products by Molecule Types, H2 2016 38 Number of Products by Stage and Molecule Types, H2 2016 38

3SBio Inc. BIOCAD Chong Kun Dang Pharmaceutical Corp. Dr. Reddy's Laboratories Limited Galenica Ltd. Panacea Biotec Limited Pfizer Inc. PharmaEssentia Corporation PhytoHealth Corporation Pieris Pharmaceuticals Inc Sandoz International GmbH SBI Pharmaceuticals Co., Ltd. Therapure Biopharma Inc. Tolero Pharmaceuticals, Inc.